Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,, Pharmacodynamics, and Tumour Response. Clinical Trial Using Intermittent dosing of AZD5363

- The folks at AstraZeneca are studying the effects of Intermittent dosing of AZD5363 on Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy,, Safety and Tolerability,, Pharmacokinetics,, Pharmacodynamics, and Tumour Response. in males ages 18 years and older. This clinical trial is slated to start October 2012 and is expected to end circa February 2015.

800-236-9933
AstraZeneca Clinical Study Information
Overall Study Contact Info
StatusName Contact Phone
RecruitingAstraZeneca Clinical Study InformationClinicalTrialTransparency@astrazeneca.com800-236-9933

This study is officially titled, "A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)."

Locations

Research Site

Southampton, United Kingdom - Recruiting

Research Site

London, United Kingdom - Recruiting

Research Site

Cardiff, Wales, United Kingdom - Recruiting

Research Site

Nashville, Tennessee - Recruiting

Research Site

Hackensack, New Jersey - Recruiting

Research Site

Ann Arbor, Michigan - Recruiting

Research Site

Boston, Massachusetts - Recruiting

Research Site

Sarasota, Florida - Recruiting

For more study details, please visit this link to ClinicalTrials.gov record, which is the source of this webpage.